BerGenBio

Regulatory Filings • Dec 14, 2021

BerGenBio to present at DNB Nordic Healthcare Conference 2021

BerGenBio to present at DNB Nordic Healthcare Conference 2021

Bergen, Norway, 14 December 2021- BerGenBio ASA (OSE:BGBIO), BerGenBio ASA (OSE:

BGBIO), a clinical-stage biopharmaceutical company developing novel, selective

AXL kinase inhibitors for severe unmet medical needs, is pleased to announce

that it will be presenting at the 12th DNB Nordic Healthcare Conference on 16th

December 2021.

The presentation will take place from 11:35 CET and will be made available on

the Company website: www.bergenbio.com/investors/presentations/

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

International Media Relations

Mary-Jane Elliott, Chris Welsh, Lucy Featherstone

Consilium Strategic Communications

bergenbio@consilium-comms.com

+44 20 3709 5700

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including immune-evasive, therapy resistant cancers. The

company's proprietary lead candidate, bemcentinib, is a potentially first-in

-class selective AXL inhibitor in a broad phase II clinical development

programme focused on combination and single agent therapy in cancer and COVID

-19. A first-in-class functional blocking anti-AXL antibody, tilvestamab, is

undergoing phase I clinical testing. In parallel, BerGenBio is developing

companion diagnostic tests to potentially identify patient populations most

likely to benefit from AXL inhibition. This is expected to facilitate more

efficient registration trials supporting a precision medicine-based

commercialisation strategy.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit?www.bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties, and other

important factors. Suchrisks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.